|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
WO1989007970A1
(en)
|
1988-03-02 |
1989-09-08 |
Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
EP1264826B1
(en)
|
2000-02-22 |
2005-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Novel imidazoline compounds
|
|
AU5752601A
(en)
|
2000-05-04 |
2001-11-12 |
Avi Biopharma Inc |
Splice-region antisense composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
JP2002253259A
(ja)
|
2001-03-02 |
2002-09-10 |
Bio Applied Systems:Kk |
抗ビスフェノールａ抗体をコードする遺伝子、組換えタンパク質およびその製造方法
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA inhibition mediated inhibition of MAP KINASE GENES
|
|
US7575886B2
(en)
|
2002-03-11 |
2009-08-18 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
|
EP2530155B1
(en)
|
2002-11-25 |
2016-03-16 |
Masafumi Matsuo |
ENA nucleic acid drugs modifying splicing in mRNA precursor
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
WO2004058717A1
(en)
|
2002-12-20 |
2004-07-15 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
AU2004299053B2
(en)
|
2003-12-15 |
2011-01-06 |
Alexion Pharmaceuticals, Inc. |
Novel anti-DC-SIGN antibodies
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
ES2627917T3
(es)
|
2004-06-28 |
2017-08-01 |
The University Of Western Australia |
Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
US7807619B2
(en)
|
2004-11-01 |
2010-10-05 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
US20070249014A1
(en)
|
2006-02-10 |
2007-10-25 |
Invitrogen Corporation |
Labeling and detection of post translationally modified proteins
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
ZA200904022B
(en)
|
2006-12-08 |
2010-08-25 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against ANGPTL3
|
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトｃ−ｆｍｓ抗原結合性タンパク質
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
SI2607484T1
(sl)
|
2008-10-27 |
2016-11-30 |
Biomarin Technologies B.V. |
Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
|
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
|
EP2427554B1
(en)
|
2009-05-08 |
2016-11-16 |
CuRNA, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
HUE040445T2
(hu)
|
2009-11-12 |
2019-03-28 |
Univ Western Australia |
Antiszensz molekulák és eljárások betegségek kezelésére
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US8859629B2
(en)
|
2010-04-27 |
2014-10-14 |
Synaffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
KR101981705B1
(ko)
|
2010-05-28 |
2019-05-24 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
SG186451A1
(en)
|
2010-07-12 |
2013-01-30 |
Covx Technologies Ireland Ltd |
Multifunctional antibody conjugates
|
|
ES2756326T3
(es)
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
EP3118316A1
(en)
|
2010-09-02 |
2017-01-18 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
AU2011349443B2
(en)
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
BR112013020273A2
(pt)
|
2011-02-08 |
2016-10-18 |
Charlotte Mecklenburg Hospital |
oligonucleotídeos antissenso
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
WO2012178173A1
(en)
|
2011-06-24 |
2012-12-27 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
JP2014534806A
(ja)
|
2011-08-23 |
2014-12-25 |
ロシュ グリクアート アーゲー |
抗ｍｃｓｐ抗体
|
|
US20130066063A1
(en)
|
2011-09-09 |
2013-03-14 |
John Cooke Hodges |
Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
|
|
EP2788026A4
(en)
|
2011-12-05 |
2015-08-05 |
Univ Duke |
V1V2 IMMUNOGENIC
|
|
CA2858576A1
(en)
|
2011-12-06 |
2013-06-13 |
Research Institute At Nationwide Children's Hospital |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
CN108588073A
(zh)
|
2011-12-28 |
2018-09-28 |
日本新药株式会社 |
反义核酸
|
|
TW201333040A
(zh)
|
2012-01-06 |
2013-08-16 |
Bioalliance Cv |
抗－輸鐵蛋白受器之抗體及其使用方法
|
|
US20130323234A1
(en)
|
2012-01-09 |
2013-12-05 |
Covx Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
|
PT2841578T
(pt)
|
2012-04-23 |
2017-08-10 |
Biomarin Tech Bv |
Resumo
|
|
CN104603271B
(zh)
|
2012-07-03 |
2019-07-19 |
马林生物科技有限公司 |
用于治疗肌肉萎缩症患者的寡核苷酸
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
EP4678239A3
(en)
|
2012-08-01 |
2026-04-08 |
Ikaika Therapeutics, Inc. |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
HRP20180268T4
(hr)
|
2012-10-23 |
2026-03-27 |
Synaffix B.V. |
Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
|
US9217148B2
(en)
|
2013-03-14 |
2015-12-22 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
HK1220154A1
(zh)
|
2013-03-15 |
2017-04-28 |
Sarepta Therapeutics, Inc. |
改进的用於治疗肌营养不良的组合物
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
CA2922544A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Engineered anti-dll3 conjugates and methods of use
|
|
AU2014321211A1
(en)
|
2013-09-23 |
2016-05-05 |
President And Fellows Of Harvard College |
Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy
|
|
WO2015057065A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
WO2015057064A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
EP3097080A1
(en)
|
2014-01-24 |
2016-11-30 |
SynAffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
CN106660967A
(zh)
|
2014-01-24 |
2017-05-10 |
西纳福克斯股份有限公司 |
(杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
|
|
JP2017513921A
(ja)
|
2014-03-03 |
2017-06-01 |
アーチャルジー、スジャータ |
ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
|
|
BR112016020618B1
(pt)
|
2014-03-12 |
2023-04-04 |
Nippon Shinyaku Co., Ltd. |
Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
|
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
CN103882024A
(zh)
|
2014-04-21 |
2014-06-25 |
石河子大学 |
一种RNAi干扰片段、RNAi干扰载体及其应用
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
AR100560A1
(es)
|
2014-05-23 |
2016-10-12 |
Genzyme Corp |
Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
|
|
PT3159409T
(pt)
|
2014-06-17 |
2020-01-21 |
Nippon Shinyaku Co Ltd |
Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
|
|
EP3177633B1
(en)
|
2014-08-04 |
2022-07-20 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
|
US9714288B2
(en)
|
2014-09-30 |
2017-07-25 |
The Regents Of The University Of California |
Antisense compounds and uses thereof
|
|
EP3733209A1
(en)
|
2014-10-03 |
2020-11-04 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
AU2015349890B2
(en)
|
2014-11-21 |
2018-08-30 |
Merck Sharp & Dohme Llc |
Insulin receptor partial agonists
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
KR102644053B1
(ko)
|
2015-05-19 |
2024-03-06 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
펩티드 올리고뉴클레오티드 콘주게이트
|
|
US10758607B2
(en)
|
2015-06-17 |
2020-09-01 |
The Research Institute At Nationwide Children's Hospital |
Respiratory syncytial virus having cleavage-resistant G protein and related materials and methods
|
|
CA2990785C
(en)
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
IL257065B
(en)
|
2015-07-22 |
2022-07-01 |
Inatherys |
Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases
|
|
HUE050061T2
(hu)
|
2015-09-15 |
2020-12-28 |
Nippon Shinyaku Co Ltd |
Antiszensz nukleinsav
|
|
EP3332008A4
(en)
|
2015-09-23 |
2019-01-16 |
Université Laval |
CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF
|
|
MA46427A
(fr)
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス， インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
EP4032902A1
(en)
|
2015-12-18 |
2022-07-27 |
Eisai R&D Management Co., Ltd. |
C-terminal lysine conjugated immunoglobulins
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
WO2017143156A1
(en)
|
2016-02-19 |
2017-08-24 |
Genisphere Llc |
Nucleic acid carriers and therapeutic methods of use
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
JP2019516679A
(ja)
|
2016-05-04 |
2019-06-20 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
生物活性剤に関する方法および組成物
|
|
TWI737736B
(zh)
|
2016-05-24 |
2021-09-01 |
美商薩羅塔治療公司 |
製備磷醯二胺嗎啉代寡聚物之方法
|
|
WO2017205191A1
(en)
|
2016-05-24 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
DK3473270T5
(da)
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
AU2017291960B2
(en)
|
2016-07-05 |
2024-03-14 |
Biomarin Technologies B.V. |
Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
US20190330626A1
(en)
*
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
BR112019009953A2
(pt)
|
2016-11-16 |
2019-10-08 |
Academisch Ziekenhuis Leiden |
substâncias direcionadas a vários órgãos ou tecidos selecionados
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
AU2017364106A1
(en)
|
2016-11-28 |
2019-06-20 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing
|
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
PT4122497T
(pt)
|
2016-12-19 |
2024-06-12 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
|
TWI833178B
(zh)
|
2016-12-26 |
2024-02-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
KR20240172236A
(ko)
|
2017-01-06 |
2024-12-09 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
CA3049791A1
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
AU2018281280B2
(en)
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
US20200155702A1
(en)
|
2017-06-16 |
2020-05-21 |
Eli Lilly And Company |
Engineered Antibody Compounds and Conjuates Thereof
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
SG11202002517RA
(en)
|
2017-09-22 |
2020-04-29 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
SG11202003126VA
(en)
|
2017-10-04 |
2020-05-28 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
MA50579A
(fr)
|
2017-11-09 |
2020-09-16 |
Crispr Therapeutics Ag |
Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
CN108220418B
(zh)
|
2017-12-29 |
2018-11-09 |
东莞博奥木华基因科技有限公司 |
基于多重pcr捕获技术的杜氏/贝氏肌营养不良症的检测试剂盒及方法
|
|
EP3735252A4
(en)
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
EP3746557A1
(en)
|
2018-01-31 |
2020-12-09 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for correcting dystrophin mutations in human cardiomyocytes
|
|
CN111683972A
(zh)
|
2018-02-05 |
2020-09-18 |
Jcr制药股份有限公司 |
用于将药剂递送至肌肉的方法
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
JP2021521140A
(ja)
|
2018-04-12 |
2021-08-26 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
WO2019209764A2
(en)
|
2018-04-26 |
2019-10-31 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers and oligomer conjugates for muscular dystrophy
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
AU2019266550A1
(en)
|
2018-05-11 |
2020-11-26 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20220251551A1
(en)
|
2018-06-13 |
2022-08-11 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
|
WO2019246480A1
(en)
|
2018-06-21 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
EP3830127A4
(en)
|
2018-08-02 |
2022-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN112955154A
(zh)
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
CA3108386A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
CA3108328A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
|
|
CN112930193A
(zh)
|
2018-08-02 |
2021-06-08 |
达因疗法公司 |
肌肉靶向复合物及其在治疗肌肉萎缩中的用途
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
AU2019315593B2
(en)
|
2018-08-02 |
2026-05-21 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
CN109306375A
(zh)
|
2018-10-16 |
2019-02-05 |
上海瀚垚生物医学科技有限公司 |
EvaGreen法数字PCR检测DMD拷贝数变异的引物、检测试剂盒及其检测方法
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
EP3876998A1
(en)
|
2018-11-05 |
2021-09-15 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
AU2019392928A1
(en)
|
2018-12-06 |
2021-06-17 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
JP2022516515A
(ja)
|
2018-12-31 |
2022-02-28 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止
|
|
EP3946376A1
(en)
|
2019-03-28 |
2022-02-09 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
JP7581252B2
(ja)
|
2019-06-06 |
2024-11-12 |
アビディティー バイオサイエンシーズ，インク． |
Ｕｎａアミダイトおよびその使用
|
|
WO2020247782A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
CN114025805B
(zh)
|
2019-06-07 |
2025-01-24 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
EP3987029A1
(en)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
EP3997228A4
(en)
|
2019-07-09 |
2024-05-15 |
The Governors of the University of Alberta |
SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
|
|
CN120775052A
(zh)
|
2019-10-10 |
2025-10-14 |
再凌生物医药(香港)有限公司 |
靶向bcma的具有人猴交叉的人源化单克隆抗体
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP2023503644A
(ja)
|
2019-11-27 |
2023-01-31 |
ディー・ティー・エックス・ファーマ・インコーポレイテッド |
デュシェンヌ型筋ジストロフィーの治療のための化合物および方法
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
EP4087653A4
(en)
|
2020-01-10 |
2024-06-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN115427448A
(zh)
|
2020-01-10 |
2022-12-02 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
CN122124274A
(zh)
|
2020-01-10 |
2026-06-02 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
US20230111212A1
(en)
|
2020-01-10 |
2023-04-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
JP7858532B2
(ja)
|
2020-01-10 |
2026-05-14 |
ダイン セラピューティクス，インコーポレーテッド |
筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
US20230117883A1
(en)
|
2020-01-24 |
2023-04-20 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
IL295022A
(en)
|
2020-01-31 |
2022-09-01 |
Dyne Therapeutics Inc |
Antibody against transferrin receptor and uses thereof
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
KR102927945B1
(ko)
|
2020-03-27 |
2026-02-23 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
|
US20230330246A1
(en)
|
2020-05-05 |
2023-10-19 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
CN116348139A
(zh)
|
2020-07-23 |
2023-06-27 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP4185320A4
(en)
|
2020-07-23 |
2025-10-08 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
AU2021313058A1
(en)
|
2020-07-23 |
2023-03-30 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
MX2023000958A
(es)
|
2020-07-23 |
2023-04-14 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica.
|
|
US20230256112A1
(en)
|
2020-07-23 |
2023-08-17 |
Dyne Therapeutics, lnc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
MX2023000984A
(es)
|
2020-07-23 |
2023-05-03 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
|
|
KR20230079068A
(ko)
|
2020-09-03 |
2023-06-05 |
다인 세라퓨틱스, 인크. |
단백질-올리고뉴클레오티드 복합체의 제조 방법
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
KR20230117182A
(ko)
|
2020-12-04 |
2023-08-07 |
다인 세라퓨틱스, 인크. |
항체-올리고뉴클레오티드 복합체 및 그의 용도
|
|
EP4271478A4
(en)
|
2020-12-31 |
2025-03-26 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR TREATING FACIOSCAPULOHUMERAL MYOPATHY
|
|
AU2021414227A1
(en)
|
2020-12-31 |
2023-07-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
KR20240009393A
(ko)
|
2021-03-31 |
2024-01-22 |
엔트라다 테라퓨틱스, 인크. |
사이클릭 세포 침투 펩티드
|
|
EP4314298A4
(en)
|
2021-04-02 |
2026-06-03 |
Avidity Biosciences Inc |
ANTIBODY-OLIGONUCLEOTIDE CONJUGATES AND ANTIBODY-PEPTIDE-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND EXON-SKIPPING INDUCTION METHODS
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
WO2022232478A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
WO2022240758A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
EP4359534A4
(en)
|
2021-06-21 |
2026-07-22 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES IN THE TREATMENT OF POMPE DISEASE
|
|
CA3222816A1
(en)
|
2021-06-21 |
2022-12-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
JPWO2022270585A1
(enExample)
|
2021-06-23 |
2022-12-29 |
|
|
|
US20240318176A1
(en)
|
2021-07-09 |
2024-09-26 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
CN118591391A
(zh)
|
2021-07-09 |
2024-09-03 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
EP4366774A4
(en)
|
2021-07-09 |
2025-11-19 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN118401553A
(zh)
|
2021-07-09 |
2024-07-26 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
JP2024525613A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
CA3226298A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283623A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
EP4389891A4
(en)
|
2021-08-19 |
2025-10-29 |
Univ Nat Corp Tokyo Medical & Dental |
MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
|
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
|
|
EP4395831A1
(en)
|
2021-09-01 |
2024-07-10 |
Entrada Therapeutics, Inc. |
Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
|
|
IL311507A
(en)
|
2021-09-16 |
2024-05-01 |
Dyne Therapeutics Inc |
Dosing of muscle targeting complexes for the treatment of dystrophinopathy
|
|
EP4426356A1
(en)
|
2021-11-01 |
2024-09-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating dystrophinopathies
|
|
JP2024546436A
(ja)
|
2021-11-12 |
2024-12-24 |
ダイン セラピューティクス，インコーポレーテッド |
顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
US20250082759A1
(en)
|
2021-12-22 |
2025-03-13 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
EP4452281A1
(en)
|
2021-12-22 |
2024-10-30 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
|
|
CA3240612A1
(en)
|
2021-12-22 |
2023-06-29 |
Miriam Verena Bujny |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
EP4469576A4
(en)
|
2022-01-27 |
2026-04-15 |
Univ Alberta |
Antisense therapeutic products conjugate to pre-MIARN splicing modulating peptides for the treatment of diseases
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
EP4493693A1
(en)
|
2022-03-17 |
2025-01-22 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
WO2023201324A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
US20250249117A1
(en)
|
2022-04-15 |
2025-08-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating myotonic dystrophy
|
|
WO2024011135A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
AU2023303022A1
(en)
|
2022-07-06 |
2025-01-02 |
Dyne Therapeutics, Inc. |
Cns targeting complexes and uses thereof
|
|
EP4590311A2
(en)
|
2022-09-21 |
2025-07-30 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
|
JP2026503873A
(ja)
|
2022-10-31 |
2026-02-02 |
ダイン セラピューティクス，インコーポレーテッド |
Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用
|
|
IL321025A
(en)
|
2022-11-21 |
2025-07-01 |
Pepgen Inc |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024149282A1
(en)
|
2023-01-10 |
2024-07-18 |
Ausperbio Therapeutics Inc. |
Modified multi-segmented antisense oligonucleotides for use
|
|
AU2024230817A1
(en)
|
2023-02-27 |
2025-09-11 |
Dyne Therapeutics, Inc. |
Methods and compositions for inhibiting progression of intramuscular fibrosis
|
|
EP4788835A1
(en)
|
2023-10-06 |
2026-08-12 |
Dyne Therapeutics, Inc. |
Biomarkers for repeat expansion diseases
|
|
WO2025147541A1
(en)
|
2024-01-02 |
2025-07-10 |
Dyne Therapeutics, Inc. |
Methods and compositions for treating myotonic dystrophy
|